Elegen
Signal active
Organization
Contact Information
Overview
Elegen is a biotechnology company that develops microfluidic technology. It is driven by a mission to deploy this technology in a new generation of DNA synthesizers aimed at enabling and accelerating biomedical advances.
The company was founded in 2017 and led by Dr. Matthew Hill.
About
Industries
Biotechnology, Life Science, Health Care
Founded
2017
Employees
11-50
Headquarters locations
United States, North America
Social
N/A
Profile Resume
Elegen headquartered in United States, North America, operates in the Biotechnology, Life Science, Health Care sector. The company focuses on Biotechnology and has secured $840.0M in funding across 24 round(s). With a team of 11-50 employees, Elegen is actively contributing to advancements in Biotechnology. Their latest funding round, Series B - Elegen, raised $35.0M. Discover more about their projects, partnerships, and impact on our platform.
Funding Rounds
Funding rounds
2
Investors
11
Lead Investors
0
Total Funding Amount
$35.0M
Details
2
Elegen has raised a total of $35.0M in funding over 2 rounds.
| Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
|---|---|---|---|---|
| 2020 | Seed | |||
| 2024 | Early Stage Venture | 35.0M |
Investors
Elegen is funded by 18 investors.
| Investor Name | Lead Investor | Funding Round | Partners |
|---|---|---|---|
| Cain McClary | - | FUNDING ROUND - Cain McClary | 35.0M |
| KdT Ventures | - | FUNDING ROUND - KdT Ventures | 35.0M |
| Elegen | - | FUNDING ROUND - Elegen | 35.0M |
| 8VC | - | FUNDING ROUND - 8VC | 35.0M |
Recent Activity
There is no recent news or activity for this profile.